April 25, 2018 / 12:06 PM / a month ago

GSK rules out entering Shire takeover battle

LONDON (Reuters) - GlaxoSmithKline’s (GSK.L) chief executive said on Wednesday she had no interest in acquiring Shire (SHP.L), the London-listed rare diseases specialist that Takeda Pharmaceutical (4502.T) hopes to buy for some $64 billion.

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

Emma Walmsley, speaking to reporters after first-quarter results, said the British drugmaker’s focus was on deals to acquire early-stage experimental drugs that would help rebuild the company’s pharmaceuticals pipeline.

    Reporting by Ben Hirschler; editing by Jason Neely

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below